<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Pediatric Hematology/Oncology and Immunopathology</journal-id><journal-title-group><journal-title xml:lang="en">Pediatric Hematology/Oncology and Immunopathology</journal-title><trans-title-group xml:lang="ru"><trans-title>Вопросы гематологии/онкологии и иммунопатологии в педиатрии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-1708</issn><issn publication-format="electronic">2414-9314</issn><publisher><publisher-name xml:lang="en">Fund Doctors, Innovations, Science for Children</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">183</article-id><article-id pub-id-type="doi">10.24287/1726-1708-2018-17-2-114-120</article-id><article-categories><subj-group subj-group-type="toc-heading"><subject>ШКОЛА ИММУНОЛОГА</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Clinical case of IgG4-related disease</article-title><trans-title-group xml:lang="ru"><trans-title>Клинический случай IgG4-ассоциированного заболевания</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7846-3473</contrib-id><name-alternatives><name xml:lang="en"><surname>Sagoyan</surname><given-names>G. B.</given-names></name><name xml:lang="ru"><surname>Сагоян</surname><given-names>Г.Б.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3664-2876</contrib-id><name-alternatives><name xml:lang="en"><surname>Abramov</surname><given-names>D. S.</given-names></name><name xml:lang="ru"><surname>Абрамов</surname><given-names>Д.С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8208-2075</contrib-id><name-alternatives><name xml:lang="en"><surname>Deordieva</surname><given-names>E. A.</given-names></name><name xml:lang="ru"><surname>Деордиева</surname><given-names>Е.А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Burlakov</surname><given-names>V. I.</given-names></name><name xml:lang="ru"><surname>Бурлаков</surname><given-names>В.И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7317-7104</contrib-id><name-alternatives><name xml:lang="en"><surname>Tereshchenko</surname><given-names>G. V.</given-names></name><name xml:lang="ru"><surname>Терещенко</surname><given-names>Г.В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2869-6535</contrib-id><name-alternatives><name xml:lang="en"><surname>Kozlova</surname><given-names>A. L.</given-names></name><name xml:lang="ru"><surname>Козлова</surname><given-names>А.Л.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Department of immunology</p><p>Russia 117997, Moscow, Samory Mashela st., 1</p></bio><email>annamax-99@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2018-09-20" publication-format="electronic"><day>20</day><month>09</month><year>2018</year></pub-date><volume>17</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>114</fpage><lpage>120</lpage><history><date date-type="received" iso-8601-date="2018-09-20"><day>20</day><month>09</month><year>2018</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 1970, «D. Rogachev NMRCPHOI»</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 1970, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России</copyright-statement><copyright-year>1970</copyright-year><copyright-holder xml:lang="en">«D. Rogachev NMRCPHOI»</copyright-holder><copyright-holder xml:lang="ru">ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://hemoncim.com/jour/article/view/183">https://hemoncim.com/jour/article/view/183</self-uri><abstract xml:lang="en"><p>IgG4-related disease is an extremely rare disorder, сcharacterized by the inflammatory infiltration of various organs, with predominance of IgG4-positive plasma cells, fibrosis and high IgG4 plasma concentration. Treatment regiments have not been optimized, especially in children. Here we discuss a case of IgG4-related disease of the orbit in a 13 year old boy and our new treatment approach involving JAK-kinase inhibitor ruxolitininb. The article also presents analysis of the state of the problem of IgG4-related disease it he world, including terminology, historical references, pathogenesis, diagnostic problems  and clinical manifestations.</p></abstract><trans-abstract xml:lang="ru"><p>IgG4-связанное заболевание - крайне редкое, характеризующееся воспалительной инфильтрацией различных органов с преобладанием IgG4-положительных плазмоцитов, фиброзом и повышением концентрации IgG4 в крови. Подходы к его терапии не оптимизированы, особенно в педиатрической группе пациентов. В статье обсуждается случай IgG4-связанного заболевания орбиты у мальчика 13 лет, рассмотрен новый вариант терапевтического подхода при этой патологии с применением ингибитора JAK-киназ - руксолитиниба. Представлен анализ современного состояния проблемы IgG4-связанного заболевания в мире, затрагивающий аспекты терминологии, исторические справки, патогенез, проблемы диагностики и клинические проявления.</p></trans-abstract><kwd-group xml:lang="en"><kwd>IgG4-related disease</kwd><kwd>children</kwd><kwd>orbita</kwd><kwd>treatment</kwd><kwd>JAK-inhibitor</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>IgG4-связанное заболевание</kwd><kwd>дети</kwd><kwd>орбита</kwd><kwd>лечение</kwd><kwd>ингибитор JAK-киназ</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Kamisawa T., Zen Y., Pillai S., et al. IgG4-related disease. Lancet 2015; 385 (9976): 1460-71.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Okazaki K., Uchida K., Ikeura T. Current concept and diagnosis of IgG4-related disease in the hepato-bilio-pancreatic system. J Gastroenterol 2013; 48 (3): 303-14.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Mikulicz J. Uber eine eigenartige symmetrishe Erkrankung der Tranen und Mundspeicheldrusen. Stuttgart: Beitr z Chir Fesrschrf Theodor Billroth 1892: p. 610-30.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Kuttner H. Uber entzundiche Tumoren der submaaxilla ren Speicheldruse. Beitr Klin Chir 1896; 15: 815-34.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Comings D.E., Skubi K.B., Van Eyes J., Motulsky A.G. Familial multifocal fibrosclerosis. Ann Intern Med 1967; 66: 884-92.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Okamoto T., Kamisawa A. Autoimmune pancreatitis: proposal of IgG4related sclerosing disease. J Gastroenterol 2006; 41: 613-25.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Masaki Y., Dong L., Kurose N., Kitaga-wa K, Morikawa Y., Yamamoto M., et al. Proposal for a new clinical entity, IgG4-positive multi-organ lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders. Ann Rheum Dis 2009; 68: 1310-5.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Yamamoto M., Takahashi H., Ohara M., Suzuki C., Naishiro Y., Yamamoto H., et al. A new conceptualization for Mikulicz’s disease as an IgG4-related plasmacytic disease. Mod Rheumatol 2006; 16: 335-40.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Umehara H., Okazaki K., Masaki Y., Kawano M., Yamamoto M., Saeki T, et al. A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Mod Rheumatol 2012; 22 (1): 1-14.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Uchida K., Masamune A., Shimose-gawa T., Okazaki K., et. al. Prevalence of IgG4-related disease in Japan based on nationwide survey in 2009. Int J Rheumatol 2012; e358371.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Stone J.H., Patel V.I., Oliveira G.R., Stone J.Rl. Case records of the Massachusetts General Hospital. Case 38-2012. A 60-year-old man with abdominal pain and aortic aneurysms. N Engl J Med 2012; 367 (24): 2335-46.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Karim F., Loeffen J., Bramer W., Westernberg L., Verdijk R., Haden M, et. al. IgG4-related disease: a systematic review of this unrecognized disease in pediatrics. Pediatric Rheumatology 2016; 14: 18.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Kawa S., Ota M., Yoshizawa K., Horiu-chi A., Hamano H., Ochi Y., et. al. HLA DRB10405-DQB10401 haplotype is associated with autoimmune pancreatitis in the Japanese population. Gastroenterology 2002; 122 (5): 1264-9.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Chang M.C., Chang Y.T., Tien Y.W., Lian P.C., Jan I.S., Wei S.C., et.al. T-cell regulatory gene CTLA-4 polymorphism/haplotype association with autoimmune pancreatitis. Clin Chem 2007; 53 (9): 1700-5.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Umemura T., Ota M., Hamano H., Katsuyama Y., Kiyosawa K., Kawa S. Genetic association of Fc receptor-like 3 polymorphisms with autoimmune pancreatitis in Japanese patients. Gut 2006; 55 (9): 1367-8.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Umemura T., Ota M., Hamano H., Katsuyama Y., Muraki T., Arakura N., et. al. Association of autoimmune pancreatitis with cytotoxic T-lymphocyte antigen 4 gene polymorphisms in Japanese patients. Am J Gastroenterol 2008; 103 (3): 588-94.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Masaki Y., Dong L., Kurose N., Kitaga-wa K., Morikawa Y., Yamamoto M., et al. Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders. Ann Rheum Dis 2009; 68: 1310.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Guarneri F., Guarneri C., Benvenga S. Helicobacter pylori and autoimmune pancreatitis: role of carbonic anhydrase via molecular mimicry? J Cell Mol Med 2005; 9(3): 741-4.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Yadlapati S., Verheyen E., Efthimiou P. IgG4-related disease: a complex under diagnosed clinical entity. Rheumatol Int 2018; 38 (2): 169-77.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Frulloni L., Lunardi C., Simone R., Dolcino M., Scattolini C., Falconi M., et. al. Identification of a novel antibody associated with autoimmune pancreatitis. N Engl J Med 2009; 361 (22): 2135-42.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Zen Y., Fujii T., Harada K., Kawano M., Yamada K., Takahira M., et al. Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis. Hepatology 2007; 45: 1538.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Björnsson E. Immunoglobulin G4-associated cholangitis. Curr Opin Gastroenterol 2008; 24: 389.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Mattoo H., Mahajan V.S., Maehara T., Deshpande V., Della-Torre E., Wallace Z., et al. Clonal expansion of CD4(+) cytotoxic T lymphocytes in patients with IgG4-related disease. J Allergy Clin Immunol 2016; 138: 825.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Kalapesi F.B., Garrott H.M., Moldovan C. IgG4 Orbital Inflammation in a 5-Year-Old Child Presenting as an Orbital Mass. Informa Healthcare USA 2013; 32 (2): 137-40.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Lee C.S., Harocopos G.J., Kraus C.L., Lee A.Y., Van Stavern G. P., Couch S. M., et. al. IgG4-associated orbital and ocular inflammation. Journal of ophthalmic inflammation and infection 2015; 5: 15.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Soliotis F., Mavragani C.P., Plastiras S.C., Rontogianni D., Skopouli F.N., Moutsopoulos H.M. IgG4-related disease: a rheumatologist’s perspective. Clin Exp Rheumatol 2014; 32: 724.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Nakano S., Takeda I., Kitamura K., Watahiki H., Iimura Y., Takenaka M. Vanishing tumor of the abdomen in patient with Sjogren’s syndrome. Am J Dig Dis 1978; 23 (5): 75-9.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Kamisawa T., Shimosegawa T., Okaza-ki K., Nishino T., Watanabe H., Kanno A., et. al. Standard steroid treatment for autoimmune pancreatitis. Gut 2009; 58 (11): 1504-7.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Umehara H., Okazaki K., Masaki Y., Kawano M., Yamamoto M., Saeki T., et al. Comprehensive diagnostic criteria for IgG4-relataed disease, 2011. Mod Rheumatol 2012; 22 (1): 21-30.</mixed-citation></ref><ref id="B30"><label>30.</label><citation-alternatives><mixed-citation xml:lang="en">Kim H.M., Chung M.J., Chung J.B. Remission and relapse of autoimmune pancreatitis: focusing on corticosteroid treatment. Pancreas 2010; 39 (5): 555-60.</mixed-citation><mixed-citation xml:lang="ru">Kim H.M., Chung M.J., Chung J.B. Remission and relapse of autoimmune pancreatitis: focusing on corticosteroid treatment. Pancreas 2010; 39 (5): 555-60.</mixed-citation></citation-alternatives></ref><ref id="B31"><label>31.</label><mixed-citation>Kamisawa T., Okazaki K., Kawa S., Ito T., Inui K., Irie H., et al. Amendment of the Japanese Consensus Guidelines for Autoimmune Pancreatitis, 2013 III. Treatment and prognosis of autoimmune pancreatitis. J Gastroenterol 2014; 49 (6): 961-70.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Saeki T., Kawano M., Mizushima I., Yamamoto M., Wada Y., Nakashima H., et al. The clinical course of patients with IgG4-related kidney disease. Kidney Int. 2013; 84 (4): 826-33.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Hirano K., Tada M., Isayama H., Yagioka H., Sasaki T., Kogure H., et. al. Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment. Gut 2007; 56 (12): 1719-24.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Wu A., Andrew N.H., Tsirbas A., Tan P., Gajdatsy A., Selva D., et. al. Rituximab for the treatment of IgG4-related orbital disease: experience from five cases. Eye (Lond) 2015; 29 (1): 122-8.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Khosroshahi A., Bloch D.B., Deshpande V., Stone J.H. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum 2010; 62 (6): 1755-62.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Hart P.A., Topazian M.P., Witzig T.E., Clain J.E., Gleeson F.C., Klebig R.R., et. al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut 2013; 62 (11): 1607-15.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Della-Torre E., Campochiaro C., Bozzo-lo E.P., Dagna L., Scotti R., Nicoletti R., et. al. Methotrexate for maintenance of remission in IgG4-related disease. Rheumatology (Oxford) 2015; 54 (10): 1934-6.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Carruthers M.N., Topazian M.P., Khos-roshahi A., Witzig T., Wallace Z., Hart P., et al. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis 2015; 74 (6): 1171-7.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Kozlova A., Burlakov V., Abramov D., Sagoyan G., Shcherbina A. A case report of a pediatric patient with orbital IgG4-related disease. PRES 2017, RPeS-ABS-1402.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Aalberse R.C., Stapel S.O., Schuurman J., Rispens T. Immunoglobulin G4: an odd antibody. Clin Exp Allergy 2009; 39: 469.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Liu L.J., Chen M., Yu F.,Zhao M., Wang H. IgG subclass distribution, affinity of anti-myeloperoxidase antibodies in sera from patients with Wegener's granulomatosis and microscopic polyangiitis. Nephrology (Carlton) 2008; 13: 629.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Zen Y., Nakanuma Y. Pathogenesis of IgG4-related disease. Curr Opin Rheumatol 2011; 23: 114.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Horvath C.M. The JAK-STAT pathway stimulated by interferon gamma. Sci STKE 2004: 260.</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Frank D.A., Robertson M.S., Bonni A., Ritz J., Greenberg M. Interleukin 2 signaling involves the phosphorylation of STAT proteins. Proc Natl Acad Shi USA 1995; 92 (17): 7779-83.</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Busch-Dienstfertig M., Gonzalez-Rod-riguez S. IL-4, JAK-STAT signaling and pain. JAK STAT 2013; 2 (4): е27638.</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Siang H., Harris M. B., Rothman P. IL4/IL13 signaling beyong JAK/STAT. J Allergy Clin Immunol 2000; 105 (6 Pt. 1): 1063-70.</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Razdrak K., Stafford S., Alam R. The activation of the Jak-STAT1 signaling pathway by IL - in eosinophils. J Immunol 1995; 155 (1): 397-402.</mixed-citation></ref></ref-list></back></article>
